SlideShare una empresa de Scribd logo
  BIOTECH 2011  The Impact of a Powerful Payer:  Reimbursement and Pricing Roadmap Demonstrating Value in the Era of a Powerful Payer Nathan White, CPC Executive Director, Access & Reimbursement inVentiv Patient Access Solutions inVentiv Health October 24, 2011
Learning Objectives ,[object Object],[object Object],[object Object],[object Object],[object Object]
What is evidence-based medicine? ,[object Object],[object Object]
Number of Occurrences of Value Terminology by Year in Core Clinical Journals SOURCE: Reich, S., & White, N. (2010). Speaking of Value in Healthcare: The Need for Common Understanding of Terminology.  Poster Session, International Society for Medical Publication Professionals.
Percent of Increase of Occurrences of Value Terminology from 2006 to 2009 in Core Clinical Journals SOURCE: Reich, S., & White, N. (2010). Speaking of Value in Healthcare: The Need for Common Understanding of Terminology.  Poster Session, International Society for Medical Publication Professionals.
How Do We Define Value?
The Value Equation:  Safety + Efficacy + Comparative Cost/Clinical Effectiveness Industry ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
What is Evidence Used For? ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Who Needs Real World Evidence? ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],WellPoint's CER Guide Describes How It Will Determine Usefulness Of Studies  Observational Studies Of "Real-World" Questions   The guidelines state that, "while randomized, controlled clinical trials remain the gold standard for producing reliable efficacy and safety data, WellPoint recognizes that there are circumstances in which RCTs alone may not be sufficient for decision-making.  Accordingly, a well-conducted CER or observational study may complement RCT-based information by providing effectiveness data, or data on outcomes achieved in a 'real-world' setting.“ ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Patient Centered Outcomes Research Institute (PCORI) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Patient Centered Outcomes Research Institute (PCORI) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
SOURCE:  National Pharmaceutical Council, PCORI Methodology Committee: Resource Guide, February 2011
European HTA/Payer Landscape ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
US HTA/Payer Landscape ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
BCBS TEC Criteria ,[object Object],[object Object],[object Object],[object Object],[object Object]
Evidence Development:  Pre- and Post-Approval ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Post-approval Research Today – Safety & Value ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
The Future of Payer-Industry Relationships?  Innovative Contracts! Innovative Contracting Contract Types Performance-Based Contracts ,[object Object],[object Object],[object Object],Risk-Sharing Agreements ,[object Object],[object Object],[object Object],Traditional With a “Twist” ,[object Object],[object Object],2 3 1
A Glimpse Into the Future ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Benefit Design Shift  ,[object Object],[object Object],[object Object],Outcomes Focus ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Value Focus ,[object Object],[object Object],[object Object],[object Object],Cost Reduction ,[object Object],[object Object],[object Object],Cost Shifting Trends in Benefit Management Objectives of Innovative Contracts Cost Reduction Risk Shifting ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Budget Predictability Budget Predictability Trends mentioned in benefit management align well with the goals of innovative contracting.  1 2 3 1 2 3 4 4
How Do We Communicate  Value To Payers? Principles of Payer Communication Simplicity ,[object Object],[object Object],Transparency ,[object Object],[object Object],Credibility ,[object Object],[object Object],Successful communication with payers requires following three principles: II III I
Organizational Requirements Hypothesis  Validation Evidence Generation Value Communication Rigorous Scientist Credible Ambassador  Strategic Visionary The right value evidence needs to be delivered to the right audience at the right time by the right people.  Stakeholder mapping and engagement is pivotal in rolling out the study outputs efficiently and effectively.
Final Thoughts ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Más contenido relacionado

La actualidad más candente

Integrating Laboratory Services
Integrating Laboratory ServicesIntegrating Laboratory Services
Integrating Laboratory ServicesMedpace
 
What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...
What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...
What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...Nathan White, CPC
 
Integration of HEOR into Global Publication Plans
Integration of HEOR into Global Publication PlansIntegration of HEOR into Global Publication Plans
Integration of HEOR into Global Publication PlansDr. Kavita Lamror
 
WHITE PAPER: What’s Next in US Payor Communications: The Impact of FDA's Prop...
WHITE PAPER: What’s Next in US Payor Communications: The Impact of FDA's Prop...WHITE PAPER: What’s Next in US Payor Communications: The Impact of FDA's Prop...
WHITE PAPER: What’s Next in US Payor Communications: The Impact of FDA's Prop...Nathan White, CPC
 
Basics of pharmacoeconomics_and_outcomes_research (2)
Basics of pharmacoeconomics_and_outcomes_research (2)Basics of pharmacoeconomics_and_outcomes_research (2)
Basics of pharmacoeconomics_and_outcomes_research (2)Arlen Meyers, MD, MBA
 
How do we get and pay for new antibiotics?
How do we get and pay for new antibiotics? How do we get and pay for new antibiotics?
How do we get and pay for new antibiotics? atowse
 
Finding the Right Care for the Right Price, Cost and Quality (Geof Baker)
Finding the Right Care for the Right Price, Cost and Quality (Geof Baker)Finding the Right Care for the Right Price, Cost and Quality (Geof Baker)
Finding the Right Care for the Right Price, Cost and Quality (Geof Baker)Geof Baker
 
1.3.2 Healthcare and Pharmaceuticals
1.3.2 Healthcare and Pharmaceuticals1.3.2 Healthcare and Pharmaceuticals
1.3.2 Healthcare and PharmaceuticalsMari-Nadin G.
 
Incorporating Life-cycle Price Modelling into Pharmaceutical Cost-effectivene...
Incorporating Life-cycle Price Modelling into Pharmaceutical Cost-effectivene...Incorporating Life-cycle Price Modelling into Pharmaceutical Cost-effectivene...
Incorporating Life-cycle Price Modelling into Pharmaceutical Cost-effectivene...Office of Health Economics
 
HTA training - Dr Roisin Adams - March 27th 2016
HTA training - Dr Roisin Adams - March 27th 2016HTA training - Dr Roisin Adams - March 27th 2016
HTA training - Dr Roisin Adams - March 27th 2016ipposi
 
Health Technology Assessment- Overview
Health Technology Assessment- OverviewHealth Technology Assessment- Overview
Health Technology Assessment- Overviewshashi sinha
 
Microsoft in Healthcare Analytics Georgia HIMSS
Microsoft in Healthcare Analytics Georgia HIMSS Microsoft in Healthcare Analytics Georgia HIMSS
Microsoft in Healthcare Analytics Georgia HIMSS Perficient, Inc.
 
Using Stated Preferences to Guide Health Care Resource Allocation Decisions
Using Stated Preferences to Guide Health Care Resource Allocation Decisions  Using Stated Preferences to Guide Health Care Resource Allocation Decisions
Using Stated Preferences to Guide Health Care Resource Allocation Decisions Office of Health Economics
 
Moving Beyond the QALY in Patient-Centered Value Frameworks: But, in What Di...
Moving  Beyond the QALY in Patient-Centered Value Frameworks: But, in What Di...Moving  Beyond the QALY in Patient-Centered Value Frameworks: But, in What Di...
Moving Beyond the QALY in Patient-Centered Value Frameworks: But, in What Di...Office of Health Economics
 
Should Drug Prices Differ by Indication? Outlining the debate on indication-b...
Should Drug Prices Differ by Indication? Outlining the debate on indication-b...Should Drug Prices Differ by Indication? Outlining the debate on indication-b...
Should Drug Prices Differ by Indication? Outlining the debate on indication-b...Office of Health Economics
 

La actualidad más candente (20)

Integrating Laboratory Services
Integrating Laboratory ServicesIntegrating Laboratory Services
Integrating Laboratory Services
 
What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...
What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...
What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...
 
Integration of HEOR into Global Publication Plans
Integration of HEOR into Global Publication PlansIntegration of HEOR into Global Publication Plans
Integration of HEOR into Global Publication Plans
 
WHITE PAPER: What’s Next in US Payor Communications: The Impact of FDA's Prop...
WHITE PAPER: What’s Next in US Payor Communications: The Impact of FDA's Prop...WHITE PAPER: What’s Next in US Payor Communications: The Impact of FDA's Prop...
WHITE PAPER: What’s Next in US Payor Communications: The Impact of FDA's Prop...
 
Basics of pharmacoeconomics_and_outcomes_research (2)
Basics of pharmacoeconomics_and_outcomes_research (2)Basics of pharmacoeconomics_and_outcomes_research (2)
Basics of pharmacoeconomics_and_outcomes_research (2)
 
How do we get and pay for new antibiotics?
How do we get and pay for new antibiotics? How do we get and pay for new antibiotics?
How do we get and pay for new antibiotics?
 
Finding the Right Care for the Right Price, Cost and Quality (Geof Baker)
Finding the Right Care for the Right Price, Cost and Quality (Geof Baker)Finding the Right Care for the Right Price, Cost and Quality (Geof Baker)
Finding the Right Care for the Right Price, Cost and Quality (Geof Baker)
 
1.3.2 Healthcare and Pharmaceuticals
1.3.2 Healthcare and Pharmaceuticals1.3.2 Healthcare and Pharmaceuticals
1.3.2 Healthcare and Pharmaceuticals
 
Incorporating Life-cycle Price Modelling into Pharmaceutical Cost-effectivene...
Incorporating Life-cycle Price Modelling into Pharmaceutical Cost-effectivene...Incorporating Life-cycle Price Modelling into Pharmaceutical Cost-effectivene...
Incorporating Life-cycle Price Modelling into Pharmaceutical Cost-effectivene...
 
Antibiotics and the Economics of Innovation
Antibiotics and the Economics of InnovationAntibiotics and the Economics of Innovation
Antibiotics and the Economics of Innovation
 
HTA training - Dr Roisin Adams - March 27th 2016
HTA training - Dr Roisin Adams - March 27th 2016HTA training - Dr Roisin Adams - March 27th 2016
HTA training - Dr Roisin Adams - March 27th 2016
 
Regulation reimbursement and evidence on NMT
Regulation reimbursement and evidence on NMTRegulation reimbursement and evidence on NMT
Regulation reimbursement and evidence on NMT
 
Health Technology Assessment- Overview
Health Technology Assessment- OverviewHealth Technology Assessment- Overview
Health Technology Assessment- Overview
 
Managed Entry Agreements in Asia
Managed Entry Agreements in Asia Managed Entry Agreements in Asia
Managed Entry Agreements in Asia
 
Microsoft in Healthcare Analytics Georgia HIMSS
Microsoft in Healthcare Analytics Georgia HIMSS Microsoft in Healthcare Analytics Georgia HIMSS
Microsoft in Healthcare Analytics Georgia HIMSS
 
Using Stated Preferences to Guide Health Care Resource Allocation Decisions
Using Stated Preferences to Guide Health Care Resource Allocation Decisions  Using Stated Preferences to Guide Health Care Resource Allocation Decisions
Using Stated Preferences to Guide Health Care Resource Allocation Decisions
 
Adaptive licensing cirs_akt_oct2014
Adaptive licensing cirs_akt_oct2014Adaptive licensing cirs_akt_oct2014
Adaptive licensing cirs_akt_oct2014
 
Moving Beyond the QALY in Patient-Centered Value Frameworks: But, in What Di...
Moving  Beyond the QALY in Patient-Centered Value Frameworks: But, in What Di...Moving  Beyond the QALY in Patient-Centered Value Frameworks: But, in What Di...
Moving Beyond the QALY in Patient-Centered Value Frameworks: But, in What Di...
 
What can we learn from other countries?
What can we learn from other countries?What can we learn from other countries?
What can we learn from other countries?
 
Should Drug Prices Differ by Indication? Outlining the debate on indication-b...
Should Drug Prices Differ by Indication? Outlining the debate on indication-b...Should Drug Prices Differ by Indication? Outlining the debate on indication-b...
Should Drug Prices Differ by Indication? Outlining the debate on indication-b...
 

Similar a BIOTECH 2011 NJ/DE/PA Case studies

The Patient Journey
The Patient JourneyThe Patient Journey
The Patient JourneyCovance
 
The Rise of Value-Based Contracting for Biopharmaceuticals and Medical Techno...
The Rise of Value-Based Contracting for Biopharmaceuticals and Medical Techno...The Rise of Value-Based Contracting for Biopharmaceuticals and Medical Techno...
The Rise of Value-Based Contracting for Biopharmaceuticals and Medical Techno...Nathan White, CPC
 
Reimbursement Basics For Life Science Entrepreneurs
Reimbursement Basics For Life Science EntrepreneursReimbursement Basics For Life Science Entrepreneurs
Reimbursement Basics For Life Science EntrepreneursEdward Berger
 
Fda Cms Summit Panel Preso In Ventiv
Fda Cms Summit Panel Preso In VentivFda Cms Summit Panel Preso In Ventiv
Fda Cms Summit Panel Preso In VentivNathan White, CPC
 
Minute Interview: Value Based Procurement
Minute Interview: Value Based ProcurementMinute Interview: Value Based Procurement
Minute Interview: Value Based ProcurementThe MarkeTech Group
 
The Role of Real-World Evidence in Supporting a Product's Value Story
The Role of Real-World Evidence in Supporting a Product's Value StoryThe Role of Real-World Evidence in Supporting a Product's Value Story
The Role of Real-World Evidence in Supporting a Product's Value StoryCovance
 
Daniel Jackson, UCB
Daniel Jackson, UCBDaniel Jackson, UCB
Daniel Jackson, UCBGoPrezi
 
Real-World Evidence: A Better Life Journey for Pharmas, Payers and Patients
Real-World Evidence: A Better Life Journey for Pharmas, Payers and PatientsReal-World Evidence: A Better Life Journey for Pharmas, Payers and Patients
Real-World Evidence: A Better Life Journey for Pharmas, Payers and PatientsCognizant
 
Pharmacoeconomic Assessment through Market Approval and Beyond: Theory and Op...
Pharmacoeconomic Assessment through Market Approval and Beyond: Theory and Op...Pharmacoeconomic Assessment through Market Approval and Beyond: Theory and Op...
Pharmacoeconomic Assessment through Market Approval and Beyond: Theory and Op...Medpace
 
Strategic Sourcing Ppt Final
Strategic Sourcing   Ppt FinalStrategic Sourcing   Ppt Final
Strategic Sourcing Ppt FinalSunayan Pal
 
Advanced Diagnostics in the Post-PAMA Era
Advanced Diagnostics in the Post-PAMA EraAdvanced Diagnostics in the Post-PAMA Era
Advanced Diagnostics in the Post-PAMA EraJohn Hanna
 
DHP Research Patient Reported Outcome (PRO) Measures Workshop
DHP Research Patient Reported Outcome (PRO) Measures WorkshopDHP Research Patient Reported Outcome (PRO) Measures Workshop
DHP Research Patient Reported Outcome (PRO) Measures WorkshopKeith Meadows
 
Highlights from ExL Pharma's 2nd Pharmaceutical Managed Markets
Highlights from ExL Pharma's  2nd Pharmaceutical Managed MarketsHighlights from ExL Pharma's  2nd Pharmaceutical Managed Markets
Highlights from ExL Pharma's 2nd Pharmaceutical Managed MarketsExL Pharma
 
Late Phase Presentation
Late Phase PresentationLate Phase Presentation
Late Phase PresentationDavid Selkirk
 
NCBI Bookshelf. A service of the National Library of Medicine,.docx
NCBI Bookshelf. A service of the National Library of Medicine,.docxNCBI Bookshelf. A service of the National Library of Medicine,.docx
NCBI Bookshelf. A service of the National Library of Medicine,.docxvannagoforth
 
Value based healthcare
Value based healthcareValue based healthcare
Value based healthcareAsem Shadid
 

Similar a BIOTECH 2011 NJ/DE/PA Case studies (20)

The Patient Journey
The Patient JourneyThe Patient Journey
The Patient Journey
 
The Rise of Value-Based Contracting for Biopharmaceuticals and Medical Techno...
The Rise of Value-Based Contracting for Biopharmaceuticals and Medical Techno...The Rise of Value-Based Contracting for Biopharmaceuticals and Medical Techno...
The Rise of Value-Based Contracting for Biopharmaceuticals and Medical Techno...
 
Reimbursement Basics For Life Science Entrepreneurs
Reimbursement Basics For Life Science EntrepreneursReimbursement Basics For Life Science Entrepreneurs
Reimbursement Basics For Life Science Entrepreneurs
 
Fda Cms Summit Panel Preso In Ventiv
Fda Cms Summit Panel Preso In VentivFda Cms Summit Panel Preso In Ventiv
Fda Cms Summit Panel Preso In Ventiv
 
Minute Interview: Value Based Procurement
Minute Interview: Value Based ProcurementMinute Interview: Value Based Procurement
Minute Interview: Value Based Procurement
 
The Role of Real-World Evidence in Supporting a Product's Value Story
The Role of Real-World Evidence in Supporting a Product's Value StoryThe Role of Real-World Evidence in Supporting a Product's Value Story
The Role of Real-World Evidence in Supporting a Product's Value Story
 
Daniel Jackson, UCB
Daniel Jackson, UCBDaniel Jackson, UCB
Daniel Jackson, UCB
 
HTA Uncovered february 2014
HTA Uncovered february 2014HTA Uncovered february 2014
HTA Uncovered february 2014
 
Real-World Evidence: A Better Life Journey for Pharmas, Payers and Patients
Real-World Evidence: A Better Life Journey for Pharmas, Payers and PatientsReal-World Evidence: A Better Life Journey for Pharmas, Payers and Patients
Real-World Evidence: A Better Life Journey for Pharmas, Payers and Patients
 
Pharmacoeconomic Assessment through Market Approval and Beyond: Theory and Op...
Pharmacoeconomic Assessment through Market Approval and Beyond: Theory and Op...Pharmacoeconomic Assessment through Market Approval and Beyond: Theory and Op...
Pharmacoeconomic Assessment through Market Approval and Beyond: Theory and Op...
 
Strategic Sourcing Ppt Final
Strategic Sourcing   Ppt FinalStrategic Sourcing   Ppt Final
Strategic Sourcing Ppt Final
 
Advanced Diagnostics in the Post-PAMA Era
Advanced Diagnostics in the Post-PAMA EraAdvanced Diagnostics in the Post-PAMA Era
Advanced Diagnostics in the Post-PAMA Era
 
Webinar - Pharmacy Strategies for Purchasers
Webinar - Pharmacy Strategies for PurchasersWebinar - Pharmacy Strategies for Purchasers
Webinar - Pharmacy Strategies for Purchasers
 
DHP Research Patient Reported Outcome (PRO) Measures Workshop
DHP Research Patient Reported Outcome (PRO) Measures WorkshopDHP Research Patient Reported Outcome (PRO) Measures Workshop
DHP Research Patient Reported Outcome (PRO) Measures Workshop
 
ADAPTIVE PATHWAYS
ADAPTIVE PATHWAYSADAPTIVE PATHWAYS
ADAPTIVE PATHWAYS
 
Highlights from ExL Pharma's 2nd Pharmaceutical Managed Markets
Highlights from ExL Pharma's  2nd Pharmaceutical Managed MarketsHighlights from ExL Pharma's  2nd Pharmaceutical Managed Markets
Highlights from ExL Pharma's 2nd Pharmaceutical Managed Markets
 
Late Phase Presentation
Late Phase PresentationLate Phase Presentation
Late Phase Presentation
 
NCBI Bookshelf. A service of the National Library of Medicine,.docx
NCBI Bookshelf. A service of the National Library of Medicine,.docxNCBI Bookshelf. A service of the National Library of Medicine,.docx
NCBI Bookshelf. A service of the National Library of Medicine,.docx
 
Value based healthcare
Value based healthcareValue based healthcare
Value based healthcare
 
Abpi rd conference_towse_ 20_nov_2014
Abpi rd conference_towse_ 20_nov_2014Abpi rd conference_towse_ 20_nov_2014
Abpi rd conference_towse_ 20_nov_2014
 

Más de Nathan White, CPC

F5 Outcomes based contracting 040416 ARSmm
F5 Outcomes based contracting 040416 ARSmmF5 Outcomes based contracting 040416 ARSmm
F5 Outcomes based contracting 040416 ARSmmNathan White, CPC
 
EBI inVentiv Market Access Virtual Conference
EBI inVentiv Market Access Virtual ConferenceEBI inVentiv Market Access Virtual Conference
EBI inVentiv Market Access Virtual ConferenceNathan White, CPC
 
BIOTECH 2011 A POWERFUL PAYER: PRICING & REIMBURSEMENT ROADMAP
BIOTECH 2011 A POWERFUL PAYER: PRICING & REIMBURSEMENT ROADMAPBIOTECH 2011 A POWERFUL PAYER: PRICING & REIMBURSEMENT ROADMAP
BIOTECH 2011 A POWERFUL PAYER: PRICING & REIMBURSEMENT ROADMAPNathan White, CPC
 
340 b coalition presentation
340 b coalition presentation340 b coalition presentation
340 b coalition presentationNathan White, CPC
 
BIO Windhover Pharmaceutical Strategic Alliances Conference April 2011
BIO Windhover Pharmaceutical Strategic Alliances Conference April 2011BIO Windhover Pharmaceutical Strategic Alliances Conference April 2011
BIO Windhover Pharmaceutical Strategic Alliances Conference April 2011Nathan White, CPC
 
WEBINAR: Developing Payer Evidence: The Role of Post Approval Programs
WEBINAR: Developing Payer Evidence: The Role of Post Approval ProgramsWEBINAR: Developing Payer Evidence: The Role of Post Approval Programs
WEBINAR: Developing Payer Evidence: The Role of Post Approval ProgramsNathan White, CPC
 
BIOTECH 2011 NJ/PA/DE Case Studies
BIOTECH 2011 NJ/PA/DE Case StudiesBIOTECH 2011 NJ/PA/DE Case Studies
BIOTECH 2011 NJ/PA/DE Case StudiesNathan White, CPC
 
Poster Presented at ISMPP, April 2010
Poster Presented at ISMPP, April 2010Poster Presented at ISMPP, April 2010
Poster Presented at ISMPP, April 2010Nathan White, CPC
 

Más de Nathan White, CPC (9)

F5 Outcomes based contracting 040416 ARSmm
F5 Outcomes based contracting 040416 ARSmmF5 Outcomes based contracting 040416 ARSmm
F5 Outcomes based contracting 040416 ARSmm
 
EBI inVentiv Market Access Virtual Conference
EBI inVentiv Market Access Virtual ConferenceEBI inVentiv Market Access Virtual Conference
EBI inVentiv Market Access Virtual Conference
 
CMAC 2011 Presentation
CMAC 2011 PresentationCMAC 2011 Presentation
CMAC 2011 Presentation
 
BIOTECH 2011 A POWERFUL PAYER: PRICING & REIMBURSEMENT ROADMAP
BIOTECH 2011 A POWERFUL PAYER: PRICING & REIMBURSEMENT ROADMAPBIOTECH 2011 A POWERFUL PAYER: PRICING & REIMBURSEMENT ROADMAP
BIOTECH 2011 A POWERFUL PAYER: PRICING & REIMBURSEMENT ROADMAP
 
340 b coalition presentation
340 b coalition presentation340 b coalition presentation
340 b coalition presentation
 
BIO Windhover Pharmaceutical Strategic Alliances Conference April 2011
BIO Windhover Pharmaceutical Strategic Alliances Conference April 2011BIO Windhover Pharmaceutical Strategic Alliances Conference April 2011
BIO Windhover Pharmaceutical Strategic Alliances Conference April 2011
 
WEBINAR: Developing Payer Evidence: The Role of Post Approval Programs
WEBINAR: Developing Payer Evidence: The Role of Post Approval ProgramsWEBINAR: Developing Payer Evidence: The Role of Post Approval Programs
WEBINAR: Developing Payer Evidence: The Role of Post Approval Programs
 
BIOTECH 2011 NJ/PA/DE Case Studies
BIOTECH 2011 NJ/PA/DE Case StudiesBIOTECH 2011 NJ/PA/DE Case Studies
BIOTECH 2011 NJ/PA/DE Case Studies
 
Poster Presented at ISMPP, April 2010
Poster Presented at ISMPP, April 2010Poster Presented at ISMPP, April 2010
Poster Presented at ISMPP, April 2010
 

Último

Antiplatelets in IHD, Dose Duration, DAPT vs SAPT
Antiplatelets in IHD, Dose Duration, DAPT vs SAPTAntiplatelets in IHD, Dose Duration, DAPT vs SAPT
Antiplatelets in IHD, Dose Duration, DAPT vs SAPTAkashGanganePatil1
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
 
Aptopadesha Pramana / Pariksha: The Verbal Testimony
Aptopadesha Pramana / Pariksha: The Verbal TestimonyAptopadesha Pramana / Pariksha: The Verbal Testimony
Aptopadesha Pramana / Pariksha: The Verbal TestimonyDr KHALID B.M
 
Creating Accessible Public Health Communications
Creating Accessible Public Health CommunicationsCreating Accessible Public Health Communications
Creating Accessible Public Health Communicationskatiequigley33
 
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...PhRMA
 
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...Catherine Liao
 
End Feel -joint end feel - Normal and Abnormal end feel
End Feel -joint end feel - Normal and Abnormal end feelEnd Feel -joint end feel - Normal and Abnormal end feel
End Feel -joint end feel - Normal and Abnormal end feeldranji1
 
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1DR SETH JOTHAM
 
Circulation through Special Regions -characteristics and regulation
Circulation through Special Regions -characteristics and regulationCirculation through Special Regions -characteristics and regulation
Circulation through Special Regions -characteristics and regulationMedicoseAcademics
 
DECIPHERING COMMON ECG FINDINGS IN ED.pptx
DECIPHERING COMMON ECG FINDINGS IN ED.pptxDECIPHERING COMMON ECG FINDINGS IN ED.pptx
DECIPHERING COMMON ECG FINDINGS IN ED.pptxdrwaque
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramLevi Shapiro
 
NCLEX RN REVIEW EXAM CONTENT BLUE BOOK PDF
NCLEX RN REVIEW EXAM CONTENT BLUE BOOK PDFNCLEX RN REVIEW EXAM CONTENT BLUE BOOK PDF
NCLEX RN REVIEW EXAM CONTENT BLUE BOOK PDFShahid Hussain
 
Relationship between vascular system disfunction, neurofluid flow and Alzheim...
Relationship between vascular system disfunction, neurofluid flow and Alzheim...Relationship between vascular system disfunction, neurofluid flow and Alzheim...
Relationship between vascular system disfunction, neurofluid flow and Alzheim...Catherine Liao
 
A thorough review of supernormal conduction.pptx
A thorough review of supernormal conduction.pptxA thorough review of supernormal conduction.pptx
A thorough review of supernormal conduction.pptxSergio Pinski
 
Final CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptx
Final CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptxFinal CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptx
Final CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptxgauripg8
 
180-hour Power Capsules For Men In Ghana
180-hour Power Capsules For Men In Ghana180-hour Power Capsules For Men In Ghana
180-hour Power Capsules For Men In Ghanahealthwatchghana
 
linearity concept of significance, standard deviation, chi square test, stude...
linearity concept of significance, standard deviation, chi square test, stude...linearity concept of significance, standard deviation, chi square test, stude...
linearity concept of significance, standard deviation, chi square test, stude...KavyasriPuttamreddy
 
Cervical screening – taking care of your health flipchart (Vietnamese)
Cervical screening – taking care of your health flipchart (Vietnamese)Cervical screening – taking care of your health flipchart (Vietnamese)
Cervical screening – taking care of your health flipchart (Vietnamese)Cancer Institute NSW
 
DIGITAL RADIOGRAPHY-SABBU KHATOON .pptx
DIGITAL RADIOGRAPHY-SABBU KHATOON  .pptxDIGITAL RADIOGRAPHY-SABBU KHATOON  .pptx
DIGITAL RADIOGRAPHY-SABBU KHATOON .pptxSabbu Khatoon
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...Catherine Liao
 

Último (20)

Antiplatelets in IHD, Dose Duration, DAPT vs SAPT
Antiplatelets in IHD, Dose Duration, DAPT vs SAPTAntiplatelets in IHD, Dose Duration, DAPT vs SAPT
Antiplatelets in IHD, Dose Duration, DAPT vs SAPT
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
 
Aptopadesha Pramana / Pariksha: The Verbal Testimony
Aptopadesha Pramana / Pariksha: The Verbal TestimonyAptopadesha Pramana / Pariksha: The Verbal Testimony
Aptopadesha Pramana / Pariksha: The Verbal Testimony
 
Creating Accessible Public Health Communications
Creating Accessible Public Health CommunicationsCreating Accessible Public Health Communications
Creating Accessible Public Health Communications
 
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
 
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
 
End Feel -joint end feel - Normal and Abnormal end feel
End Feel -joint end feel - Normal and Abnormal end feelEnd Feel -joint end feel - Normal and Abnormal end feel
End Feel -joint end feel - Normal and Abnormal end feel
 
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
 
Circulation through Special Regions -characteristics and regulation
Circulation through Special Regions -characteristics and regulationCirculation through Special Regions -characteristics and regulation
Circulation through Special Regions -characteristics and regulation
 
DECIPHERING COMMON ECG FINDINGS IN ED.pptx
DECIPHERING COMMON ECG FINDINGS IN ED.pptxDECIPHERING COMMON ECG FINDINGS IN ED.pptx
DECIPHERING COMMON ECG FINDINGS IN ED.pptx
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
 
NCLEX RN REVIEW EXAM CONTENT BLUE BOOK PDF
NCLEX RN REVIEW EXAM CONTENT BLUE BOOK PDFNCLEX RN REVIEW EXAM CONTENT BLUE BOOK PDF
NCLEX RN REVIEW EXAM CONTENT BLUE BOOK PDF
 
Relationship between vascular system disfunction, neurofluid flow and Alzheim...
Relationship between vascular system disfunction, neurofluid flow and Alzheim...Relationship between vascular system disfunction, neurofluid flow and Alzheim...
Relationship between vascular system disfunction, neurofluid flow and Alzheim...
 
A thorough review of supernormal conduction.pptx
A thorough review of supernormal conduction.pptxA thorough review of supernormal conduction.pptx
A thorough review of supernormal conduction.pptx
 
Final CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptx
Final CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptxFinal CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptx
Final CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptx
 
180-hour Power Capsules For Men In Ghana
180-hour Power Capsules For Men In Ghana180-hour Power Capsules For Men In Ghana
180-hour Power Capsules For Men In Ghana
 
linearity concept of significance, standard deviation, chi square test, stude...
linearity concept of significance, standard deviation, chi square test, stude...linearity concept of significance, standard deviation, chi square test, stude...
linearity concept of significance, standard deviation, chi square test, stude...
 
Cervical screening – taking care of your health flipchart (Vietnamese)
Cervical screening – taking care of your health flipchart (Vietnamese)Cervical screening – taking care of your health flipchart (Vietnamese)
Cervical screening – taking care of your health flipchart (Vietnamese)
 
DIGITAL RADIOGRAPHY-SABBU KHATOON .pptx
DIGITAL RADIOGRAPHY-SABBU KHATOON  .pptxDIGITAL RADIOGRAPHY-SABBU KHATOON  .pptx
DIGITAL RADIOGRAPHY-SABBU KHATOON .pptx
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
 

BIOTECH 2011 NJ/DE/PA Case studies

  • 1. BIOTECH 2011 The Impact of a Powerful Payer: Reimbursement and Pricing Roadmap Demonstrating Value in the Era of a Powerful Payer Nathan White, CPC Executive Director, Access & Reimbursement inVentiv Patient Access Solutions inVentiv Health October 24, 2011
  • 2.
  • 3.
  • 4. Number of Occurrences of Value Terminology by Year in Core Clinical Journals SOURCE: Reich, S., & White, N. (2010). Speaking of Value in Healthcare: The Need for Common Understanding of Terminology. Poster Session, International Society for Medical Publication Professionals.
  • 5. Percent of Increase of Occurrences of Value Terminology from 2006 to 2009 in Core Clinical Journals SOURCE: Reich, S., & White, N. (2010). Speaking of Value in Healthcare: The Need for Common Understanding of Terminology. Poster Session, International Society for Medical Publication Professionals.
  • 6. How Do We Define Value?
  • 7.
  • 8.
  • 9.
  • 10.
  • 11.
  • 12. SOURCE: National Pharmaceutical Council, PCORI Methodology Committee: Resource Guide, February 2011
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.
  • 19.
  • 20.
  • 21.
  • 22. Organizational Requirements Hypothesis Validation Evidence Generation Value Communication Rigorous Scientist Credible Ambassador Strategic Visionary The right value evidence needs to be delivered to the right audience at the right time by the right people. Stakeholder mapping and engagement is pivotal in rolling out the study outputs efficiently and effectively.
  • 23.